Single- and multi-tablet HIV regimens go head-to-head

"Many of us [clinicians] default to using single-tablet regimens."

1

Single-tablet and multi-tablet HIV regimens showed similar rates of viral suppression in Washington state Medicaid enrollees.
2

Viral suppression was 91.6% for the single-tablet regimen compared to 88.9% for multi-tablet regimens, but the difference was not statistically significant.
3

Housing status significantly impacted viral suppression rates, with lower suppression among those experiencing unstable housing.
4

Bictegravir/emtricitabine/tenofovir alafenamide is approximately 77% more expensive than some dolutegravir-based multi-tablet alternatives.
5

The study suggests a need for a holistic approach to HIV treatment that considers effectiveness, cost, and patient preferences.

1